Loading…
Tibet-based drugmaker; main product Xinhuosu, an injected recombinant BNP drug for acute heart failure, plus Tibetan and Chinese medicines.
Tibet-based drugmaker; main product Xinhuosu, an injected recombinant BNP drug for acute heart failure, plus Tibetan and Chinese medicines.
Relies on one drug: Xinhuosu, an injection for acute heart failure that has been the only product of its type made in China, so most sales come from a single product under hospital purchasing rules. Its older Tibetan-herb lines, such as the rhodiola capsules, are far smaller. Capacity is being expanded to meet demand.
Moat: narrow (IP / patents, regulatory licence). Xinhuosu has long been the only domestic product of its kind, a national class-1 biologic.
Founded: 1999 · Employees: 671
Size Tibet Rhodiola Pharmaceutical (600211.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.95B, the 1294th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥40.37 on 6 Nov 2026.
Performance Over six months the shares fell 0.2%, against -10.0% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 12.8% over the last twelve months (peer median +9.4%); the operating margin is 27.5% (peer median 15.0%).
Valuation It trades at 13.0× forward earnings against a peer median of 22.5× (5th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 31.3 points above its cost of capital (7.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.07B | CN¥2.95B | CN¥2.78B | CN¥3.10B | CN¥2.53B |
| Revenue growth | — | +6% | -11% | +23% | — |
| Gross profit | CN¥2.89B | CN¥2.74B | CN¥2.58B | CN¥2.92B | CN¥2.35B |
| EBITDA | n/a | CN¥1.00B | CN¥968M | CN¥1.10B | CN¥759M |
| Net income | CN¥992M | CN¥938M | CN¥1.05B | CN¥801M | CN¥370M |
| Free cash flow | CN¥1.10B | CN¥1.01B | CN¥979M | CN¥1.06B | CN¥748M |
| Capital expenditure | CN¥22.1M | CN¥16.0M | CN¥37.6M | CN¥21.7M | CN¥102M |
| Total debt | CN¥1.25B | CN¥841M | CN¥273M | CN¥502M | CN¥488M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600211.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.6% | -1.7% | 4th highest of 21 |
| 6-month return | -0.2% | -10.0% | 10th highest of 21 |
| Distance from 52-week high | -17.6% | -28.8% | 7th highest of 21 |
| Revenue growth (TTM) | +12.8% | +9.4% | 9th highest of 21 |
| Operating margin | 27.5% | 15.0% | 6th highest of 21 |
| Forward P/E | 13.0× | 22.5× | 5th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -0.5% | 11.2% | 3rd least demanding of 18 |
| Growth delivered (Del g) | +16.7% | +7.8% | 4th highest of 18 |
| Hurdle (Req g minus delivered) | -17.2 pp | +0.6 pp | 4th least demanding of 18 |
| ROIC minus cost of capital | +31.3 pp | -0.4 pp | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 8.3× | 0.4% | -0.2% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |